- Q1 2024 Aclaris Therapeutics Inc Earnings Call TranscriptMay 07, 2024$1.3 (-4.55%)Earnings
- Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call TranscriptNov 13, 2023
- Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Aclaris Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2023$8.89Earnings
- Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Aclaris Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Aclaris Therapeutics Inc R&D Day (Virtual) TranscriptDec 07, 2021
- Aclaris Therapeutics Inc ATI-1777 Clinical Data Call TranscriptJun 08, 2021
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJan 19, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 17, 2020
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q4 2019 Aclaris Therapeutics Inc Earnings Call TranscriptFeb 25, 2020$1.31Earnings
- Q3 2019 Aclaris Therapeutics Inc Earnings Call TranscriptNov 07, 2019$1.17Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptOct 24, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptSep 27, 2019
- Q2 2019 Aclaris Therapeutics Inc Earnings Call TranscriptAug 08, 2019$2.12Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptJul 30, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 26, 2019
- Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study TranscriptJun 17, 2019
- Q1 2019 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2019$6.41Earnings
- Q4 2018 Aclaris Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Aclaris Therapeutics, Inc. - Special Call Transcript
Okay. Good morning, everybody. Welcome to Aclaris' R&D Day. We're excited to walk through kind of the new look of the company since making some strategic decisions over the summer.
So my name is Dr. Neal Walker. I'm the President and CEO of Aclaris. Recently, over the last few months, we decided to undertake a strategic business review, and the output of that review was to divest our commercial and near-term commercial assets and really shift from what we refer to as a fully integrated dermatology company to more of a development-stage biotech company focused primarily on immunology and inflammation.
We did this because we believe we have competitive differentiation in kinase development specifically. We have world-class leadership, as you'll see here today, in the ex-Pfizer kinase development team, and these folks are leaders in cysteinome-based targets, and that -- and we'll talk more about that as we move through the presentation.
Our focus will be on small molecule therapeutics. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)